Sept. 10, 2013
/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or
. The Phase II dose escalation and safety trial, taking place at
and at the
University of Michigan
Health System, is designed to treat up to 15 patients in five different dosing cohorts. All of the patients will be ambulatory and reside within the geographic region of the research center where they will participate. The first 12 patients will receive injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function. The final three patients will receive both cervical and lumbar injections. The dose will also increase in both number of injections and cells per injection throughout the trial. In Phase I, the trial progressed to a maximum of 15 injections of 100,000 cells each. In Phase II, the trial will advance up to a maximum of 40 injections and up to 400,000 cells per injection.
"The primary goal of our Phase II trial is identify the maximum-safe tolerated dose," said
, PhD, Neuralstem's Chairman of the Board and Chief Scientific Officer. "We also hope to transplant all of the patients in the trial by the completion of the second quarter of 2014. We are focused on cervical injections in this trial, which is the region of the spine that controls the breathing function, and where we believe we can have the strongest influence on the patients' quality of life and longevity."
Patients seeking information on the trial should contact the relevant center. For the
University of Michigan
Health System, please visit:
. For Emory Healthcare, please call (404) 778-7777.
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem's NSI-566 spinal cord-derived stem cell therapy is in an FDA-approved Phase II clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as
disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.